The Nomination Committee for Infant Bacterial Therapeutics AB for the Annual General Meeting 2027 has been appointed based on the ownership structure as of 30 June 2026.
The Nomination Committee for the Annual General Meeting 2027 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of David Dangoor (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who through direct and indirect ownership is the company's second largest shareholder, and Karsten Ferm, appointed by the shareholder Fjärde AP-fonden. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board.
Shareholders wishing to submit proposals to the Nomination Committee are welcome to contact the Chairman of the Nomination Committee by e-mail at derd@derdangoor.com or by letter:
Infant Bacterial Therapeutics AB
Att: Valberedningen
Katarina Bangata 70
116 42 Stockholm, Sweden
For further information, please contact Nigel Titford
Email: nigel.titford@ibtherapeutics.com